← All trials
NCT06376981
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2024
- Primary completion
- Dec 19, 2026
- Completion date
- Mar 19, 2027
- First posted
- Apr 22, 2024
- Last posted
- Oct 3, 2024
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centre Hospitalier Departemental VendeeLead sponsor
- Centre Hospitalier Departemental VendeeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.